urolithiasis. Calculus of kidney with calculus of ureter
Conditions
Interventions
Intervention 1: Intervention group: Patients will receive empagliflozin 10 mg daily for 4 weeks. Intervention 2: Control group: Patients will receive daily Starch tablets that look similar to Empaglif
Sponsors
Hamedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients in the age range of 18 to 65 years Patients with a history of kidney stones in the last 5 years
Exclusion criteria
Exclusion criteria: Diabetic patients Taking antidiabetic drugs Taking diuretic drugs Chronic kidney disease patients pregnancy Patients with genital infections Patients with urinary infections breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour urine calcium. Timepoint: Before the intervention and 4 weeks after the Start of Empagliflozin. Method of measurement: The ratio of urinary calcium to 24-hour urine volume.;24 hour Urine Oxalate. Timepoint: Before the intervention and 4 weeks after the Start of Empagliflozin. Method of measurement: The ratio of urinary Oxalate to 24-hour urine volume.;24 hour urine Uric acid. Timepoint: Before the intervention and 4 weeks after the Start of Empagliflozin. Method of measurement: The ratio of urinary Uric acid to 24-hour urine volume.;24 hour urine Phosphate. Timepoint: Before the intervention and 4 weeks after the Start of Empagliflozin. Method of measurement: The ratio of urinary Uric acid to 24-hour urine volume. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmir Mohammad Ataie
Hamedan University of Medical Sciences
Outcome results
None listed